Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. RHYZ ANALYTICAL LABS
WARNING LETTER
•RHYZ ANALYTICAL LABS•June 5, 2025

RHYZ ANALYTICAL LABS – FDA Warning Letter, Jun 5, 2025

Record Details

On November 12, 2025, the FDA issued a Warning Letter to Rhyz Analytical Labs following an inspection from June 2 to 5, 2025, at their Provo, UT facility. The letter detailed significant violations of Current Good Manufacturing Practice (CGMP) regulations, rendering drug products tested by the company adulterated under the Federal Food, Drug, and Cosmetic Act.

Key violations included the firm"s failure to thoroughly investigate unexplained discrepancies or out-of-specification (OOS) results, particularly for microbiological tests. Rhyz Analytical Labs repeatedly concluded "unknown laboratory error" without sufficient scientific justification, relying on retest data without proper root cause analysis, and failing to assess the effectiveness of corrective and preventive actions. Additionally, the company"s Quality Unit failed to establish adequate written responsibilities and procedures, demonstrating insufficient oversight of contract testing operations, including critical processes like deviations, change control, cleaning, and laboratory investigations.

The FDA deemed the company"s responses to these observations inadequate. Rhyz Analytical Labs is required to conduct a retrospective, independent review of all invalidated OOS results from the past three years, providing scientific justification and a remediation plan for vulnerable laboratory methods. They must also submit a comprehensive remediation plan for their OOS investigation systems, addressing Quality Unit oversight, trend identification, root cause resolution, and revised procedures. Furthermore, a comprehensive assessment and remediation plan for the Quality Unit is mandated to ensure its effective functioning, including robust procedures and adequate oversight. Failure to address these violations promptly may lead to further regulatory action.

Company
RHYZ ANALYTICAL LABS
Inspection date
June 5, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Glen S. Putnam
  • Marisa Heayn
  • Francis Godwin (Director)
View Company Profile

ID · a4711da5-5afe-4cb9-a6bf-1561d1e39fd4

Violation Codes6
21 U.S.C. 351(a)(2)(B)21 CFR 210FD&C Act 501(a)(2)(B)21 CFR 211.19221 CFR 21121 CFR 211.22(d)

Full citation text and observation details available on the Dashboard.

Other documents for RHYZ ANALYTICAL LABS
  • 483 - 2025-06-05June 5, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore RHYZ ANALYTICAL LABS
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.